Kura Oncology (NASDAQ:KURA) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA) from a sell rating to a hold rating in a report released on Tuesday.

Other equities analysts also recently issued research reports about the stock. UBS Group began coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Wednesday, November 6th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a report on Monday, November 4th. Finally, Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $28.83.

Kura Oncology Stock Down 3.5 %

Kura Oncology stock opened at $15.92 on Tuesday. The firm has a 50 day moving average price of $18.50 and a 200 day moving average price of $19.92. Kura Oncology has a fifty-two week low of $8.80 and a fifty-two week high of $24.17. The company has a market capitalization of $1.24 billion, a PE ratio of -6.75 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Hedge Funds Weigh In On Kura Oncology

Large investors have recently bought and sold shares of the stock. Susquehanna Fundamental Investments LLC acquired a new position in Kura Oncology during the first quarter worth approximately $507,000. Assenagon Asset Management S.A. increased its holdings in shares of Kura Oncology by 50.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after acquiring an additional 577,732 shares during the period. Vanguard Group Inc. increased its holdings in shares of Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after acquiring an additional 28,212 shares during the period. Sofinnova Investments Inc. raised its position in Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares during the last quarter. Finally, Armistice Capital LLC boosted its stake in Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after purchasing an additional 302,000 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.